Forge Therapeutics to present at World Anti-Microbial Resistance Congress 2017
San Diego, California, September 12, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017
San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics and Evotec to present preclinical data on novel antibiotic program at 2017 ASM/ESCMID Conference
San Diego, California, August 29, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics forms scientific advisory board with world renowned antibiotic and drug development experts
San Diego, California, July 26, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics to present at 2017 Bio International Convention
SAN DIEGO, California, June 12, 2017 – Forge Therapeutics, Inc., [...]
Forge and Evotec Present First Efficacy Data for LpxC Inhibitor in UTI Model at ASM Microbe 2017
San Diego, California, June 3, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics to present new data on novel Gram-negative antibiotic program at ASM Microbe 2017
San Diego, California, May 24, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics attracts biotechnology leaders to join expanded board of directors
Board Composed of San Diego Biotech Veterans, Global Drug Development [...]
Forge Therapeutics raises $15 million to for new class of antibiotics
Forge Therapeutics, a developer of a new class of antibiotics, [...]
Forge Therapeutics raises $15m Series A financing to develop first novel Gram-negative antibiotic in decades
Series A Complements Recent CARB-X Non-Dilutive Funding Forge Is Resourced [...]